DSMB concluded that MaaT013 has a favorable benefit/risk ratio in 3rd line aGvHD 1. Primary endpoint ORR now expected in mid Q4 2024. Ongoing recruitment for Phase 2a trial PICASSO sponsored by AP-HP 3. Results expected end of 2024 or Q1 2025.
#BUSINESS #English #EG
Read more at Yahoo Finance